NEWBRY — Newbury Pharmaceuticals AB Income Statement
0.000.00%
Last trade - 00:00- SEK41.95m
- SEK49.85m
- SEK31.57m
Annual income statement for Newbury Pharmaceuticals AB, fiscal year end - August 31st, SEK millions except per share, conversion factor applied.
2021 August 31st | 2022 August 31st | 2023 August 31st | 2024 August 31st | 2025 August 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | SAS | SAS | SAS | SAS | SAS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 2.83 | 5.52 | 10.3 | 36.8 | 31.6 |
| Cost of Revenue | |||||
| Gross Profit | -2.35 | -6.16 | -6.9 | -2.94 | -5.07 |
| Selling / General / Administrative Expenses | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 8.45 | 20.2 | 29.9 | 50.9 | 53.5 |
| Operating Profit | -5.62 | -14.7 | -19.6 | -14.1 | -22 |
| Total Net Non Operating Interest Income / Expense | |||||
| Net Income Before Taxes | -5.56 | -14.7 | -19.4 | -15.4 | -23.6 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -5.56 | -14.7 | -19.4 | -15.4 | -23.9 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -5.56 | -14.7 | -19.4 | -15.4 | -23.9 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -5.56 | -14.7 | -19.4 | -15.4 | -23.9 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.253 | -0.751 | -0.995 | -0.635 | -0.675 |